5^th Pharmaceutical Chemistry Conference April 27-28, 2020 Prague, Czech Republic

Biography:

Peeravat Natrsanga has graduated his BSc (chemistry) at the age of 21 years from Rajamangala University of Technology Thanyaburi (RMUTT) and MSc (chemistry) from chulalongkorn university. Santi Tip-pyang, as my advisor. He has completed his PhD. from Mississippi State University in the USA in 1990. He has published more than 70 papers in reputed journals.

Abstract:

Two new xanthones namely cratochinone A (1) and cratochinone B (2), along with 16 known xanthones, were isolated from the roots of Cratoxylum cochinchinense. Their structures were characterized by spectroscopic methods, especially 1D and 2D NMR as well as comparison with those reported in the literature for known xanthones. All isolated compounds were evaluated for their cytotoxicity against five human cancer cell lines (KB, HeLa S-3, HT-29, MCF-7 and Hep G2 cell lines). Compounds 2, 5, and 7 showed significant cytotoxic effects against all cell lines with IC₅₀ values in the range of 0.91–9.93 μM, while 10 exhibited cytotoxicity against the KB, HeLa S-3, and HT-29 cells with IC₅₀ values of 7.39, 6.07, and 8.11 μM, respectively. Compound 12 exhibited cytotoxicity against both KB and HeLa S-3 cells with IC₅₀ values of 7.28 and 9.84 μM.

Biography:

Sobia Ahsan Halim has completed her PhD from University of Karachi, Karachi-Pakistan in 2013. She is working as an Assistant Professor in University of Nizwa, Oman. Her research interest in Computational drug designing and molecular modeling. She has published 50 papers in reputed journals and and 3 patents.             
 

Abstract:

Diabetes is an important emerging health concern. α-Glucosidase is a prime drug target of Diabetes Mellitus and its inhibitors are used as a treatment to delay carbohydrate digestion by inhibiting catalytic pocket of α-glucosidase. With the aim to design novel α-glucosidase inhibitors, we applied three folds ligand (LB-) and structure based (SB-) virtual screening (VS) protocol. Initially quantitative structure activity relationship (QSAR) modeling was performed. The QSAR model was developed by thirty-four known inhibitors and scrutinized by a test set. The QSAR model showed excellent q2 (0.86), r2 (0.73) and RMSE (0.28) values. The high cross validation correlation coefficient (r2) and low RMSE value suggests that the model is robust enough to be validated by the test set. The test set depicted excellent prediction with q2 and r2 values of 0.89 and 0.79, respectively. The model was used for further screening of novel compound against α-glucosidase. A set of 6609 compounds was retrieved from ZINC database and subjected to SBVS. After docking, the best docked compounds were selected and their pharmacokinetic (ADMET) profile was predicted in silico. Compounds with acceptable ADMET properties were taken as a test set-2 and their biological activities were predicted by QSAR model. The predicted biological activities, pharmacokinetic behavior, docking scores and protein-ligand interactions revealed that twenty-nine compounds specifically inhibit the catalytic site of α-glucosidase thus possess potential α-glucosidase inhibition in silico. These results serve as a guidelines for the rational design and development of potential novel anti-diabetic agents.

Biography:

Aimen Aljoundi has completed his M.sc of pharmacy from Durban, University of KwaZulu-Natal School of Health Sciences, South Africa, currently his currying his PhD in Molecular Bio-Computation & Drug Design Lab He has published more than 2 papers in reputed journals.

Abstract:

HSP72, a stress-inducing molecular chaperone, is a significant therapeutic target in oncology, but it has proved particularly difficult to inhibit this protein with small molecules owing to competition with the high affinity and abundance of its endogenous nucleotide substrates. Recently, unexpectedly 8-N –benzyladenosine inhibit the HSP 72 by targeting the lysin 56 instead of cyst 17. This prompted us to investigate the dynamic behind this novel drug combination. To get insight into the observed un expected interaction, molecular dynamics simulations have been employed to investigate the inhibitory mechanism as well as the structural dynamics that characterize this effect. Structural dynamic analyses indicate that the lysine bound complex has shown a more compact and stable protein conformation compared to cysteine bound complex. In addition, binding free energy calculation suggest that van der Waals energy interactions were observed to be the main energy component driving this unanticipated effect. Furthermore, per-residue energy decomposition analysis identified Tyr 40, Glu 267, and Thr 264 as key residues that contribute largely to this unpredicted effect. The findings highlighted in this study provide a molecular understanding of the dynamics and mechanisms that mediate the new drug design paradigm for HSP72 chemical probes in oncology treatment.

Biography:

Prof. Dr. Anil Batta is presently professor & Head with senior consultant in Govt. Medical College, Amritsar. He did his M.B.B.S. and M.D. in Medical Biochemistry from Govt. Medical College, Patiala in 1984 and 1991, respectively. His research interest is mainly in clinical application especially cancer and drug de-addiction. He has supervised more than 25 M.D., M.Sc. and Doctorate researches and published more than 130 international research papers. He is the chief editor of America’s Journal of Biochemistry. He is also working as advisor to the editorial board of International Journal of Biological and Medical Research. He has been deputed member Editorial Board of numerous International & National Medical Journals of Biochemistry. He has also been attached as technical advisor to various national and international conferences in Biochemistry. He has been attached as hi-tech endocrinal, genetics and automated labs of Baba Farid Univ. of Health Sciences, Faridkot. He has chaired various sessions in the Biochemistry meets. He has been designated as member Editorial Board of various in US and other European Courtiers. He is also involved in various research projects at Govt. Medical, Amritsar. He has done superspecialisation in Drug-de-addiction from PGIMER, Chandigarh.

Abstract:

All areas of radiology are constantly evolving. At times rapid advances are made because new equipment or pharmaceuticals are introduced. At others the evolution is gradual as established procedures and techniques are refined. The following review of selected areas in nuclear medicine includes both dramatic changes due to new developments and evolutionary changes in established techniques. The first section reviews the development of monoclonal antibodies for use in radioscintigraphy of neoplastic disease. Although many articles have been written about this topic over the years, the clinical applications have suddenly expanded because the Food and Drug Administration (FDA) recently approved one monoclonal antibody for use in the imaging of colorectal and ovarian cancer. It is anticipated that a number of other antibodies will be approved for clinical scintigraphy of both malignant and benign disease and immunotherapy. It is advised that the radiologist performing nuclear medicine procedures become knowledgeable about this expanding area of clinical application. The second section reviews several new radiopharmaceuticals that are being used with increasing frequency for myocardial imaging. The behavior of these tracers is different from that of thallium, and specialized imaging techniques are required. Although the clinical value of these agents is still questioned by some, they are widely used. Familiarity with this topic is recommended. The last section reviews some of the radiopharmaceuticals available for renal imaging and functional evaluation. The relatively new technetium-labeled pharmaceutical that approximates the behavior of hippuran is emphasized. New applications with the renal cortical imaging agent technetium DMSA are also reviewed. A thorough knowledge of the biologic behavior of these tracers and appropriate imaging and measurement techniques is extremely important for their appropriate clinical use.

Biography:

Hiba Zalloum is a Researcher in Hamdi Mango Center for Scientific Research at the University of Jordan. She holds a Master’s degree in Chemistry from The University of Jordan. Her practical research dealt with the synthesis, chelation and sorption properties of chelating polymers. Recently, her research interest is turning to molecular modeling and drug discovery field. She has 15 publications, 13 ISI-published articles, 2 book chapters and is now running 6 funded research projects.

Abstract:

Background: Lysine-specific demethylase is a demethylase enzyme that can remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is expressed in many cancers, where it impedes differentiation and contributes to cancer cell proliferation, cell metastasis and invasiveness, and is associated with inferior prognosis.  LSD1 is associated with its corepressor protein CoREST, and utilizes tetrahydrofolate as a cofactor to accept CH2 from the demethylation process. The fact that the cofactor is best bound to the active site inspired us to explore its interactions to LSD1/CoREST enzyme complex utilizing molecular dynamics simulation, which aids designing novel and potent inhibitors.

Objective: In this study we minted to identify a new potential LSD1/CoREST inhibitors and test the potency and the safety of such inhibitors against human neuroblastoma and fibroblast cells lines. 

Methods: We have implemented a previously derived model from the molecular dynamics simulation study and the key contacts to the active site in a subsequent structure based drug design and in-silico screening, which revealed a number of potential inhibitors toward LSD1/CoREST complex. The anti-proliferative activities of the identified compounds will be tested against neuroblastoma SH-SY5Y cancer cell line which known to highly express LSD1/CoREST complex.

Results: In-silico mining on National Cancer Institute (NCI) database identified 55 promising and structurally diverse inhibitors. Applying the abovementioned molecular modeling procedure yielded four compounds of LSD1/CoREST inhibiters with IC50 < 2µM. The four lead compounds were tested against SH-SY5Y neuroblastoma cell line that known to express high level of LSD1 and illustrated a potent activity with an IC50 ranging from 0.195 to 1.52µM. To estimate the toxicity of the selective leads, they were tested against normal fibroblast cells and scored a relatively high IC50 ranging from 0.303 to ≥ 100µM.

Conclusion: Our model revealed promising inhibitors that can be used in treating cancers that overexpress the LSD1 enzyme such as the SH-SY5Y neuroblastoma.

Biography:

Dr Rahul Hajare was fortunate enough to be recognized for hard work with scholarships from India Council of Medical Research Ministry of Health Research New Delhi scholarship including a centenary post doc National AIDS Research Institute Pune that is presented by Respected Dr. R.S.Paranjape, Immunologist and World Renowned Scientist., Retired Director & Scientist ‘G’ National AIDS Research Institute Pune.

Abstract:

Mental well-being is a critical aspect in understanding one’s overall health. In the India alone, mental illness effects one in six adults. Furthermore, 40% of those individuals who die of suicide have been diagnosed with a mental health condition. Yet, there is a paucity of research on innovative methods that help prevent suicide. The Contextual-Conceptual Therapy (CCT) model introduces an innovative way to treat suicide by working to uncover the strengths of the suicidal person and addressing a person’s true self. The CCT model was developed over the course of 11 years working with more than 16,000 suicidal students in India, and is tailored specifically for primary and secondary prevention of suicide. While there has been anecdotal evidence of the effectiveness of the CCT program, the program has yet to be formally evaluated. This qualitative research study aims to understand the impact the CCT program has had on its clients. Eleven former CCT clients were recruited to participate in semi-structured interviews. Outcomes described by participants included an increase in curiosity and self-efficacy as a means through which to decrease suicide ideation and behavior and proved to be incredibly powerful in changing long-term outcomes. This qualitative study is a first-step in providing critical insight on suicide prevention for wider dissemination. At a time when adverse mental health is impacting the lives of millions of people, the CCT program has the potential to address suicide and mental health, and foster mental well-being across diverse populations. Journal of Public Health International publishes peer-reviewed open access articles. We aim for the quality content and strive hard to keep it up by making all necessary possible arrangements. In this process, we encountered a specific instance where we oblige support from you to handle a manuscript. This particular manuscript seems closely related to your current research.

Biography:

Abdeen Mustafa Omer (BSc, MSc, PhD) is an Associate Researcher at Occupational Health Administration, Ministry of Health and Social Welfare, Khartoum, Sudan. He has been listed in the book WHO’S WHO in the World 2005, 2006, 2007 and 2010. He has published over 300 papers in peer-reviewed journals, 200 review articles, 7 books and 150 chapters in books.

Abstract:

Improving effectiveness of the public pharmacy is by switching resources towards areas of need, reducing inequalities and promoting better health. Unless there are clear incentives for pharmacists, they can move away from public sector. The public sector is rigid, bureaucratic personnel-management practices, low incentives, poor job satisfaction and unsupportive work environment compared to the private sector. Such situation demoralised pharmacists and encourages them to join the private sector. Many (65%) of surveyed private-sector pharmacists claimed they were public sector pharmacists migrated to the private sector. Although information on migration is sparse, anecdotal evidence persuasively underscores the problem. An internal flow of pharmacists plagues all states, since pharmacists move from poorer states to wealthier ones and from the public sector to the private. Strategies to meet current and future challenges in pharmacy human resources are urgently needed. Approaches that focus on the training of individuals, which do not take into account the job satisfaction (i.e. the nature of the work itself) and pharmacists' mobility, can enjoy only limited success. Increased production alone cannot compensate for weak motivation, high attrition and increasing mobility. To reverse decades of neglect, policy-makers in both (state and federal level) should begin now, first by recognising the problem and secondly by fixing it through the immediate implementation of potentially effective strategies.

Biography:

Samir Mameri obtained his PhD from the University of Strasbourg under the guidance of Dr. R. Ziessel in 2005. After posdocs in Germany (Marie-Curie), Japan (JSPS) and Belgium (ANR), he held a position of research scientist at the University of Amsterdam (ERC). In 2009, he obtained a position of Assistant Professor at the IUT Robert Schuman, with a promotion to Associate Professor in 2010. His current research targets the design and synthesis of new molecules for an application in the areas of biomedicine, catalysis and photo-magnetism using novel ligands and coordination complexes for the development of new nanostructured materials. He has published 02 patents and more than 35 papers.

Abstract:

The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in a more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development and manufacturing.

Biography:

  Muhammad Jehangir has 13 years diversified experience of Quality Control, Quality Assurance, Registration Affairs, Product development and Pharmaceutical manufacturing, Process Planning, Method development, Method validation, Statistical Methodology, Process & Cleaning Validation, Equipment Validation etc. Certificate Courses on cGMP, cGLP, Process Validation, CTD Documents, ISO 9001:2008, 13485-2003,14001-2004 have strong scientific, analytical, statistical, managerial and training skills. Currently he is working as a Senior Manager Quality Control and validation for Novamed Pharmaceuticals.It is toll manufacturing oriented company, manufacturing of companies like Getz Pharma, ICI, SEARLE, Macter, Ray, and for Sanofi-Aventis. He is also looking after the Quality of Novamed Healthcare, the nutraceutical and cosmeceutical manufacturing plant.              

Abstract:

The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in a more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development and manufacturing.

Biography:

Muhammad Jehangir has 13 years diversified experience of Quality Control, Quality Assurance, Registration Affairs, Product development and Pharmaceutical manufacturing, Process Planning, Method development, Method validation, Statistical Methodology, Process & Cleaning Validation, Equipment Validation etc. Certificate Courses on cGMP, cGLP, Process Validation, CTD Documents, ISO 9001:2008, 13485-2003,14001-2004 have strong scientific, analytical, statistical, managerial and training skills. Currently he is working as a Senior Manager Quality Control and validation for Novamed Pharmaceuticals.It is toll manufacturing oriented company, manufacturing of companies like Getz Pharma, ICI, SEARLE, Macter, Ray, and for Sanofi-Aventis. He is also looking after the Quality of Novamed Healthcare, the nutraceutical and cosmeceutical manufacturing plant.              
 

Abstract:

The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in a more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development and manufacturing.